Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.70005
Abstract: Due to cardiotoxicity concerns, the concurrent use of epirubicin and trastuzumab has not been fully studied. This study aimed to examine the cardiotoxicity and pathological complete response (pCR) rate associated with the concurrent regimens in… read more here.
Keywords: cancer; cardiotoxicity; concurrent; human epidermal ... See more keywords
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.31784
Abstract: Limited data exist on the safety of using anti–human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior… read more here.
Keywords: early breast; factor receptor; human epidermal; growth factor ... See more keywords
Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34750
Abstract: The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)‐positive tumors is based on nodal status. The authors’ objective was to evaluate pathologic nodal disease (pathologic lymph node‐positive [pN‐positive] and… read more here.
Keywords: epidermal growth; factor receptor; growth factor; human epidermal ... See more keywords
Broad‐spectrum cytotoxicity to cancer cells of Brevilaterin C from Brevibacillus laterosporus and its specific mechanism on human epidermal cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.30280
Abstract: Antimicrobial peptides (AMP) from Brevibacillus laterosporus have good prospects as clinical treatments for cancer. Nevertheless, details about their anticancer spectrum and mode of cytotoxicity remain poorly understood. A newly found AMP (named Brevilaterin C) secreted… read more here.
Keywords: cancer; cytotoxicity; brevibacillus laterosporus; human epidermal ... See more keywords
Keratinocyte-derived IL-36γ plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Toxicology"
DOI: 10.1007/s00204-019-02506-6
Abstract: Chemical leukoderma is an acquired type of vitiligo that can be initiated by various exogenous chemicals such as hydroquinone (HQ), rhododendrol (RD), or 4-tertiary butyl phenol (4-TBP). Despite the importance of epidermal keratinocytes in diverse… read more here.
Keywords: chemical leukoderma; human epidermal; epidermal melanocytes; role ... See more keywords
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Sign Up to like & getrecommendations! Published in 2021 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01182-9
Abstract: Gastric cancer is one of the most common malignancy worldwide. In unresectable or metastatic disease, the prognosis is poor and in generally less than a year. HER2 expression remains an important biomarker to lead the… read more here.
Keywords: advanced gastric; gastric cancer; human epidermal; epidermal growth ... See more keywords
An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1711-5
Abstract: BackgroundSome studies have suggested that human epidermal growth factor receptor 2 (HER2) positive is associated with poor outcomes in gastric cancer (GC), whereas another inconsistent studies make the situation confused. This meta-analysis was performed to… read more here.
Keywords: analysis; human epidermal; growth factor; epidermal growth ... See more keywords
A novel 2-oxopyrrolidine derivative (LN-53) efficiently induces Nrf-2 signaling pathway activation in human epidermal keratinocytes
Sign Up to like & getrecommendations! Published in 2025 at "Pharmacological Reports"
DOI: 10.1007/s43440-025-00757-y
Abstract: The skin is a pivotal organ that serves as a physical barrier, protecting the body from harmful substances such as pathogens, allergens, and other environmental irritants. Chronic inflammation in the skin, along with the anthropogenic… read more here.
Keywords: activation; human epidermal; epidermal keratinocytes; nrf signaling ... See more keywords
Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of surgery"
DOI: 10.1016/j.amjsurg.2016.05.018
Abstract: BACKGROUND Although identification of human epidermal growth factor receptor 2 (Her2) positive breast cancer represents one of the greatest advances over the past 3 decades, it has not been studied extensively on a national level.… read more here.
Keywords: cancer; human epidermal; her2 positive; breast cancer ... See more keywords
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Sign Up to like & getrecommendations! Published in 2017 at "Breast"
DOI: 10.1016/j.breast.2017.01.010
Abstract: Human epidermal growth factor receptor 2-positive (HER2+) breast cancer comprises approximately 15%-20% of all breast cancers and is associated with a poor prognosis. The introduction of anti-HER2 therapy has significantly improved clinical outcomes for patients… read more here.
Keywords: breast; treatment; human epidermal; breast cancer ... See more keywords
[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Sign Up to like & getrecommendations! Published in 2022 at "Bulletin du cancer"
DOI: 10.1016/j.bulcan.2021.12.009
Abstract: Overall, 2021 was marked by the confirmation of the major interest of cell cycle inhibitors for hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative advanced breast cancers with very high overall survival… read more here.
Keywords: positive human; hormone receptor; human epidermal; receptor positive ... See more keywords